share_log

微創醫療：海外監管公告

MICROPORT: An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

Hong Kong Stock Exchange ·  Apr 26 21:03
Summary by Futu AI
微創醫療科學有限公司（微創醫疗）公布其持股約40.32%的上海微創心脈醫療科技（心脈醫療科技）2024年第一季度財務報告。該報告顯示，心脈醫療科技第一季度營業收入達到358,081,405.15元人民幣，同比增長25.38%，歸屬於上市公司股東的净利润為184,296,095.55元人民幣，同比增長47.62%。研發投入合計為47,137,794.16元人民幣，占營業收入的比例為13.16%，較去年同期下降8.14個百分點。報告期內，心脈醫療科技的總資產和歸屬於上市公司股東的所有者權益分別增長了6.55%和5.17%。本季度財務報表未經審計。微創醫療科學有限公司於2024年4月26日通過聯交所網站向投資者公布此消息，以符合上市規則第13.10B條的信息披露要求。
微創醫療科學有限公司（微創醫疗）公布其持股約40.32%的上海微創心脈醫療科技（心脈醫療科技）2024年第一季度財務報告。該報告顯示，心脈醫療科技第一季度營業收入達到358,081,405.15元人民幣，同比增長25.38%，歸屬於上市公司股東的净利润為184,296,095.55元人民幣，同比增長47.62%。研發投入合計為47,137,794.16元人民幣，占營業收入的比例為13.16%，較去年同期下降8.14個百分點。報告期內，心脈醫療科技的總資產和歸屬於上市公司股東的所有者權益分別增長了6.55%和5.17%。本季度財務報表未經審計。微創醫療科學有限公司於2024年4月26日通過聯交所網站向投資者公布此消息，以符合上市規則第13.10B條的信息披露要求。
MICROCHUN MEDICAL SCIENCES CO., LTD. (MICROCHUN MEDICAL) ANNOUNCES ITS FIRST QUARTER FINANCIAL REPORT FOR 2024, WHICH OWNS APPROXIMATELY 40.32% OF ITS SHAREHOLDING OF APPROXIMATELY 40.32% OF SHANGHAI MICROCHUN HEART MEDICAL TECHNOLOGY (CARDIAC MEDICAL TECHNOLOGY). The report showed that Cardiac Medical Technology's first-quarter operating income reached RMB358,081,405.15, up 25.38% year-on-year, and net profit attributable to shareholders of listed companies was RMB184,296,095.55, an increase of 47.62% year-on-year. R&D investment totaled RMB 47,137,794.16, accounting for 13.16% of operating income, a decrease of 8.14 percentage points from the same period last year. During the reporting period, Cardiac Medical Technology's total assets and shareholders' equity of listed companies increased by 6.55% and 5.17%, respectively. The financial statements for the quarter are unaudited. Micro-Chung Medical Sciences Limited made this announcement to investors via the exchange website on April 26, 2024 in compliance with the disclosure requirements of section 13.10B of the Listing Rules.
MICROCHUN MEDICAL SCIENCES CO., LTD. (MICROCHUN MEDICAL) ANNOUNCES ITS FIRST QUARTER FINANCIAL REPORT FOR 2024, WHICH OWNS APPROXIMATELY 40.32% OF ITS SHAREHOLDING OF APPROXIMATELY 40.32% OF SHANGHAI MICROCHUN HEART MEDICAL TECHNOLOGY (CARDIAC MEDICAL TECHNOLOGY). The report showed that Cardiac Medical Technology's first-quarter operating income reached RMB358,081,405.15, up 25.38% year-on-year, and net profit attributable to shareholders of listed companies was RMB184,296,095.55, an increase of 47.62% year-on-year. R&D investment totaled RMB 47,137,794.16, accounting for 13.16% of operating income, a decrease of 8.14 percentage points from the same period last year. During the reporting period, Cardiac Medical Technology's total assets and shareholders' equity of listed companies increased by 6.55% and 5.17%, respectively. The financial statements for the quarter are unaudited. Micro-Chung Medical Sciences Limited made this announcement to investors via the exchange website on April 26, 2024 in compliance with the disclosure requirements of section 13.10B of the Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.